infliximab   

GtoPdb Ligand ID: 5004

Synonyms: cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650
infliximab is an approved drug (FDA (1998), EMA (1999))
Compound class: Antibody
Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [5].

Biosimilars:
NameTrade nameCompanyClinical PhaseIndicationsReferences
infliximab-dyyb; CT-P13Remsima; Inflectra; FlammegisCelltrion/PfizerApproved (2013 EMA, 2016 FDA)As per reference agent[1-2,8]
infliximab-abda; SB2Flixabi; RenflexisMerck/SamsungBioepisApproved (2016 EMA, 2017 FDA)As per reference agent 
infliximab-qbtx; PF-06438179Ixifi; ZesslyPfizer?SandozApproved (2017 FDA, 2018 EMA)As per reference agent[3]
NI-071 Nichi-Iko PharmaceuticalApproved (2017 Japan); Phase 3 US (NCT02990806)As per reference agent 
BCD-055 BiocadPh 3 (NCT02762838)Rheumatoid arthritis 
Infliximab-EPIRUS; BOW015InfimabEpirus BiopharmaceuticalsApproved (2014 India); Ph 3 US (NCT02683564)Rheumatoid arthritis 
infliximab-axxq; ABP710AvsolaAmgenApproved (2019 FDA)As per reference agent 
STI-002 MabTech/Sorrento Therapeutic   
Infliximab biosimilar 1 Nippon KayakuApproved (Japan 2014)As per reference agent
Two more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent [4].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

No information available.
Summary of Clinical Use
Used in the management of rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease [7] and ulcerative colitis.
Mechanism Of Action and Pharmacodynamic Effects
Infliximab binds with high affinity to soluble and transmembrane forms of TNFα thereby inhibiting its binding with its receptors, leading to a decrease in the production of proinflammatory cytokines.
External links